Logo for NRx Pharmaceuticals Inc

NRx Pharmaceuticals Investor Relations Material

Latest events

Logo for NRx Pharmaceuticals Inc

Q3 2024

NRx Pharmaceuticals
Logo for NRx Pharmaceuticals

Q3 2024

18 Nov, 2024
Logo for NRx Pharmaceuticals

Q2 2024

14 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from NRx Pharmaceuticals Inc

Access all reports
NRx Pharmaceuticals Inc. (NRXP) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for the treatment of central nervous system disorders. The company's portfolio includes ZYESAMI, an investigational drug for COVID-19 related respiratory failure, and oral therapeutics NRX-100 and NRX-101 for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company is headquartered in Wilmington, Delaware, and its shares are listed on the Nasdaq.